The Aromatase pipeline drugs market research report outlays comprehensive information on the Aromatase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Aromatase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
The report also covers products from therapy areas such as Oncology, Women’s Health, Genito Urinary System, and Hormonal Disorders which include the indications Breast Cancer, Ovarian Cancer, Disorders of the Breast, Benign Prostatic Hyperplasia, and Secondary (Hypogonadotropic) Hypogonadism. It also reviews key players involved in Aromatase targeted therapeutics development with respective active and dormant or discontinued products.
The Aromatase pipeline targets constitutes close to six molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, and Discovery stages are 2, 2, and 1 respectively. Similarly, the universities portfolio in Discovery comprises 1 molecule.
Aromatase overview
Aromatase is an enzyme that converts androgens into estrogens. It is also known as estrogen synthetase or estrogen synthase. Aromatase is a member of the cytochrome P450 superfamily, which are monooxygenases that catalyze many reactions involved in steroidogenesis.
For a complete picture of Aromatase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.